CSIMarket
 


Sana Biotechnology Inc   (SANA)
Other Ticker:  
 

Sana Biotechnology Inc 's Quick Ratio

SANA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Sana Biotechnology Inc 's Cash & cash equivalent, this led to improvement in Sana Biotechnology Inc 's Quick Ratio to 4.03, Quick Ratio remained below Sana Biotechnology Inc average.

Within Biotechnology & Pharmaceuticals industry 42 other companies have achieved higher Quick Ratio than Sana Biotechnology Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the III Quarter 2023 to 366, from total ranking in the second quarter 2023 at 582.

Explain Quick Ratio?
How much Cash & cash equivalents SANA´s has?
What are SANA´s Current Liabilities?


SANA Quick Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Current Liabilities Change -31.37 % 19.89 % 3.57 % 24.78 % 126.72 %
Y / Y Cash & cash equivalent Change -44.6 % -36.39 % -36.6 % -19.54 % -43.15 %
Quick Ratio MRQ 4.03 2.91 3.4 4.23 4.99
SANA's Total Ranking # 366 # 582 # 410 # 897 #
Seq. Current Liabilities Change -40.55 % 9.08 % -10.48 % 18.23 % 3.85 %
Seq. Cash & cash equivalent Change -17.6 % -6.7 % -28.09 % 0.2 % -5.38 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 43
Healthcare Sector # 185
Overall Market # 366


Quick Ratio Statistics
High Average Low
27.32 8.44 2.91
(Mar 31 2021)   (Jun 30 2023)




Financial Statements
Sana Biotechnology Inc 's Current Liabilities $ 67 Millions Visit SANA's Balance sheet
Sana Biotechnology Inc 's Cash & cash equivalent $ 269 Millions Visit SANA's Balance sheet
Source of SANA's Sales Visit SANA's Sales by Geography


Cumulative Sana Biotechnology Inc 's Quick Ratio

SANA's Quick Ratio for the trailling 12 Months

SANA Quick Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Current Liabilities TTM Growth -31.37 % 19.89 % 3.57 % 24.78 % 126.72 %
Y / Y Cash & cash equivalent TTM Growth -44.6 % -36.39 % -36.6 % -19.54 % -43.15 %
Quick Ratio TTM 3.61 3.86 4.49 5.03 5.64
Total Ranking TTM # 1866 # 805 # 290 # 655 #
Seq. Current Liabilities TTM Growth -40.55 % 9.08 % -10.48 % 18.23 % 3.85 %
Seq. Cash & cash equivalent TTM Growth -17.6 % -6.7 % -28.09 % 0.2 % -5.38 %


On the trailing twelve months basis In spite of the year on year decrease in SANA's Current Liabilities to $66.64 millions, cumulative Quick Ratio to 3.61 below the SANA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 77 other companies have achieved higher Quick Ratio than Sana Biotechnology Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 805 to 1866.

Explain Quick Ratio?
How much Cash & cash equivalents SANA´s has?
What are SANA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 78
Healthcare Sector # 461
Within the Market # 1866


trailing twelve months Quick Ratio Statistics
High Average Low
11.02 5.03 0.01
(Dec 31 2021)   (Mar 31 2021)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Protara Therapeutics Inc   10.93 $ 74.034  Millions$ 6.775  Millions
Vir Biotechnology Inc   10.29 $ 1,698.921  Millions$ 165.050  Millions
Ikena Oncology Inc   10.22 $ 196.933  Millions$ 19.271  Millions
Inhibrx Inc   9.99 $ 337.327  Millions$ 33.760  Millions
Invivyd Inc   9.89 $ 264.885  Millions$ 26.791  Millions
Cardiff Oncology inc   9.77 $ 81.363  Millions$ 8.330  Millions
Black Diamond Therapeutics Inc   9.57 $ 144.256  Millions$ 15.066  Millions
Solid Biosciences Inc   9.03 $ 142.884  Millions$ 15.816  Millions
Jasper Therapeutics Inc   8.72 $ 103.867  Millions$ 11.906  Millions
Springworks Therapeutics Inc   8.40 $ 422.419  Millions$ 50.283  Millions
Turnstone Biologics Corp   8.35 $ 109.221  Millions$ 13.081  Millions
Century Therapeutics inc   8.29 $ 169.505  Millions$ 20.435  Millions
Autolus Therapeutics Plc  8.00 $ 256.415  Millions$ 32.049  Millions
Atyr Pharma Inc   7.93 $ 102.131  Millions$ 12.881  Millions
Monte Rosa Therapeutics Inc   7.89 $ 178.477  Millions$ 22.609  Millions
Tscan Therapeutics Inc   7.49 $ 215.423  Millions$ 28.775  Millions
Tracon Pharmaceuticals Inc   7.19 $ 7.763  Millions$ 1.080  Millions
Immunovant Inc   6.81 $ 269.928  Millions$ 39.645  Millions
Palisade Bio Inc   6.74 $ 15.312  Millions$ 2.273  Millions
Passage Bio inc   6.70 $ 132.780  Millions$ 19.811  Millions
Humacyte Inc   6.61 $ 99.986  Millions$ 15.137  Millions
Surrozen Inc   6.51 $ 43.432  Millions$ 6.672  Millions
Allovir Inc   6.45 $ 213.318  Millions$ 33.066  Millions
Tenaya Therapeutics Inc   6.28 $ 121.753  Millions$ 19.377  Millions
Ginkgo Bioworks Holdings Inc   6.23 $ 1,049.244  Millions$ 168.462  Millions
Inhibikase Therapeutics Inc   6.14 $ 16.832  Millions$ 2.742  Millions
Zura Bio Limited  6.11 $ 103.859  Millions$ 17.012  Millions
Athira Pharma Inc   6.04 $ 172.948  Millions$ 28.622  Millions
Editas Medicine Inc   5.97 $ 349.617  Millions$ 58.603  Millions
Finch Therapeutics Group Inc   5.90 $ 28.779  Millions$ 4.879  Millions

Date modified: 2023-11-10T00:31:07+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com